

## Press release

### Medios achieves double-digit revenue growth and improves profitability

- Consolidated revenue increased to €2.1 billion (+10.4%)
- EBITDA pre<sup>1</sup> rose disproportionately by 17.8%
- EBITDA pre<sup>1</sup> margin increased to 4.5% (previous year: 4.2%)
- Earnings per share increased significantly to €0.61 (previous year: €0.51)
- Outlook for 2026: Revenue expected to be between €2.0 billion and €2.12 billion – with a further improvement in the EBITDA pre<sup>1</sup> margin to around 4.8%

Berlin, March 26, 2026 – The Medios-Group (“Medios”), a leading provider of Specialty Pharma in Europe, has published its 2025 annual report. Consolidated revenue increased by 10.4% year-over-year to €2.1 billion (previous year: €1.9 billion). EBITDA pre<sup>1</sup> rose significantly by 17.8% to €93.1 million (previous year: €79.0 million). Revenue and EBITDA pre<sup>1</sup> are thus broadly in line with the forecast. The EBITDA pre<sup>1</sup> margin improved accordingly to 4.5% (previous year: 4.2%). The Pharmaceutical Supply segment and the International Business segment, which has been part of the Group since June 2024, were the main contributors to this development. Organic growth in revenue and EBITDA pre<sup>1</sup> reached 7.0% and 2.7%, respectively. Consolidated net income after income taxes rose by 22.4% to €15.4 million (previous year: €12.5 million), resulting in an increase in earnings per share to €0.61 (previous year: €0.51).

#### All operating segments contributed to the increase in revenue

In the **Pharmaceutical Supply** segment, external revenue rose by 6.9% in the 2025 financial year to €1,688.8 million (previous year: €1,580.0 million). EBITDA pre<sup>1</sup> rose by 5.1% to €52.5 million (previous year: €50.0 million).

The **Patient-Specific Therapies** segment generated external revenue of €220.1 million (previous year: €213.6 million), representing a slight increase of 3.0%. EBITDA pre<sup>1</sup>, however, fell by 4.6% to €22.2 million (previous year: €23.3 million).

The **International Business** segment made a significant contribution to the Medios Group's positive performance in the 2025 financial year, with external revenue of €169.2 million (June to December 2024: €88.8 million) and EBITDA pre<sup>1</sup> of €29.1 million (June to December 2024: €16.3 million).

#### Further margin growth expected in the 2026 financial year

In 2026, Medios will focus on operational excellence, the harmonization of key business processes, the expansion of organic growth, and selective acquisitions.

For the 2026 financial year, the Medios Group expects revenue of €2.0 billion to €2.12 billion and EBITDA pre<sup>1</sup> of €94 million to €102 million. This would correspond to a further increase in the EBITDA pre<sup>1</sup> margin to approximately 4.8%.

### Key figures (IFRS)

| in € million                               | 2025           | 2024           | Δ in %       |
|--|----------------|----------------|--------------|
| <b>Revenue</b>                             | <b>2,078.7</b> | <b>1,883.0</b> | <b>10.4</b>  |
| Pharmaceutical Supply                      | 1,688.8        | 1,580.0        | 6.9          |
| Patient-Specific Therapies                 | 220.1          | 213.6          | 3.0          |
| International Business                     | 169.2          | 88.8           | 90.6         |
| Services                                   | 0.5            | 0.6            | -15.3        |
| <b>EBITDA pre<sup>1</sup></b>              | <b>93.1</b>    | <b>79.0</b>    | <b>17.8</b>  |
| Pharmaceutical Supply                      | 52.5           | 50.0           | 5.1          |
| Patient-Specific Therapies                 | 22.2           | 23.3           | -4.6         |
| International Business                     | 29.1           | 16.3           | 78.8         |
| Services                                   | -10.8          | -10.5          | 3.5          |
| <b>Cash flow from operating activities</b> | <b>52.3</b>    | <b>73.7</b>    | <b>-29.0</b> |
| <b>Earnings per share (in €)</b>           | <b>0.61</b>    | <b>0.51</b>    | <b>19.6</b>  |

The 2025 Annual Report is available for [download](#) on the Investor Relations website.

### Important events for the Medios Group in the 2026 financial year:

|                 |  |
|-----------------|--|
| April 15        | Metzler Small Cap Days 2026 – Frankfurt      |
| May 6           | TP ICAP Midcap Conference 2026 – Paris       |
| May 12          | Quarterly Statement as of March 31, 2026     |
| June 10         | Annual General Meeting 2026 (in-person)      |
| August 12       | Half-Year Financial Report 2026              |
| September 28/29 | Medios Capital Markets Day                   |
| November 10     | Quarterly Statement as of September 30, 2026 |

<sup>1</sup> EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and expenses for ERP-System implementation as well as for 2024 for performance-based payments for the acquisition of compounding volumes and from 2025 for one-time expenses due to change in the Executive Board as well as from 2026 for one-time expenses for efficiency improvements.

---

### **About Medios AG**

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

---

Medios AG is Germany's first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

[www.medios.group](http://www.medios.group)

More information on individualized medicine:

<https://app.medios.group/en/individualizedmedicine>

---

### **Contact**

Claudia Nickolaus  
Head of Investor & Public Relations, ESG Communications  
Medios AG  
Heidestraße 9 | 10557 Berlin  
T +49 30 232 566 800  
[ir@medios.group](mailto:ir@medios.group)  
[www.medios.ag](http://www.medios.ag)

### **Disclaimer**

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.

---

---